Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Pipeline Review, H2 2017

  • ID: 4334016
  • Report
  • 33 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Green Cross Corp
  • Novo Nordisk A/S
  • Pfizer Inc
  • Shire Plc
  • MORE
Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Pipeline Review, H2 2017

Summary:

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Tissue factor pathway inhibitor (TFPI) is a single-chain polypeptide. It inhibits factor Xa directly and in a Xa-dependent way, inhibits VIIa/tissue factor activity. It has an antithrombotic action and also the ability to associate with lipoproteins in plasma.

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Report covers products from therapy areas Hematological Disorders which include indications Hemophilia A, Hemophilia B and Hemophilia.

The latest report Tissue Factor Pathway Inhibitor - Pipeline Review, H2 2017, outlays comprehensive information on the Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)
  • The report reviews Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Green Cross Corp
  • Novo Nordisk A/S
  • Pfizer Inc
  • Shire Plc
  • MORE
Introduction

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Overview

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Companies Involved in Therapeutics Development

Bayer AG

Green Cross Corp

Novo Nordisk A/S

Pfizer Inc

Shire Plc

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Drug Profiles

BAY-1093884 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

concizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-1113A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06741086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit TFPI for Hemophilia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Dormant Products

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Discontinued Products

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Product Development Milestones

Featured News & Press Releases

Nov 30, 2015: New Data from Bayer’s Portfolio in Hematology to be Presented at ASH

Oct 30, 2015: MorphoSys Announces Clinical Milestone in Hemophilia Program with Bayer HealthCare

Feb 06, 2007: Jerini Expands Collaboration With Baxter To Develop Non-intraveneous Hemophilia Therapy

May 22, 2006: Baxter And Jerini Find Candidates For Development In Hemophilia

May 18, 2006: Baxter And Jerini Advance Program To Develop Non-Intravenous Hemophilia Therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indication, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Bayer AG, H2

Pipeline by Green Cross Corp, H2

Pipeline by Novo Nordisk A/S, H2

Pipeline by Pfizer Inc, H2

Pipeline by Shire Plc, H2

Dormant Projects, H2

Discontinued Products, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Indications, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer AG
  • Green Cross Corp
  • Novo Nordisk A/S
  • Pfizer Inc
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll